NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

$12.16
-0.19 (-1.54%)
(As of 05/8/2024 ET)
Today's Range
$11.64
$12.16
50-Day Range
$11.25
$16.72
52-Week Range
$5.65
$17.16
Volume
12.70 million shs
Average Volume
5.16 million shs
Market Capitalization
$2.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.07

Hims & Hers Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
23.9% Upside
$15.07 Price Target
Short Interest
Bearish
12.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Hims & Hers Health in the last 14 days
Based on 53 Articles This Week
Insider Trading
Selling Shares
$9.73 M Sold Last Quarter
Proj. Earnings Growth
127.27%
From $0.11 to $0.25 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

180th out of 905 stocks

Offices & Clinics Of Medical Doctors Industry

1st out of 7 stocks

HIMS stock logo

About Hims & Hers Health Stock (NYSE:HIMS)

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

HIMS Stock Price History

HIMS Stock News Headlines

Hims & Hers Health Stock Could Become a Wealth Compounder
Shares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings results. This quarter is arguably the most important quarter as it sets the tone for the rest of the year in any stock.
Hims & Hers Health Stock Could Become a Wealth Compounder (HIMS)
Hims & Hers stock could give investors the best of both stability and double-digit upside through EPS projections and price targets, especially after 1Q24
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
5/08/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Fax
N/A
Employees
1,046
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.07
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+27.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$-23,550,000.00
Pretax Margin
-2.47%

Debt

Sales & Book Value

Annual Sales
$872 million
Book Value
$1.61 per share

Miscellaneous

Free Float
146,483,000
Market Cap
$2.52 billion
Optionable
Optionable
Beta
0.97
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Andrew DudumMr. Andrew Dudum (Age 35)
    Co-Founder, Chairman & CEO
    Comp: $1.7M
  • Mr. Yemi Okupe (Age 38)
    Chief Financial Officer
    Comp: $804.05k
  • Ms. Melissa BairdMs. Melissa Baird (Age 46)
    Chief Operating Officer
    Comp: $917.67k
  • Ms. Irene A. Becklund (Age 39)
    Senior VP, Controller & Principal Accounting Officer
    Comp: $361.12k
  • Ms. Soleil Teubner Boughton (Age 45)
    Chief Legal Officer & Corporate Secretary
    Comp: $782.66k
  • Mr. Mike Chi (Age 43)
    Chief Marketing Officer
    Comp: $514.77k
  • Dr. Patrick Carroll M.D. (Age 66)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $27.03k
  • Ms. Khobi Brooklyn
    Chief Communications Officer
  • Ms. Amee Parekh
    Senior Vice President of Human Resources
  • Dr. Peter Stahl M.D.
    Senior VP & Member of Medical Advisory Board

HIMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price target for 2024?

15 Wall Street analysts have issued 12 month price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.07 in the next year. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2024?

Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 36.6% and is now trading at $12.16.
View the best growth stocks for 2024 here
.

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 17,470,000 shares, an increase of 34.6% from the March 31st total of 12,980,000 shares. Based on an average daily trading volume, of 5,020,000 shares, the short-interest ratio is currently 3.5 days. Currently, 12.5% of the company's shares are sold short.
View Hims & Hers Health's Short Interest
.

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our HIMS earnings forecast
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) issued its quarterly earnings results on Monday, May, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health's quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) EPS.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health updated its second quarter 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $292.0 million-$297.0 million, compared to the consensus revenue estimate of $288.1 million.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mckinley Capital Management LLC (0.30%), Mirae Asset Global Investments Co. Ltd. (0.13%), Swiss National Bank (0.13%), Summit Trail Advisors LLC (0.13%), Quantbot Technologies LP (0.10%) and GSA Capital Partners LLP (0.10%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends
.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HIMS) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners